213 related articles for article (PubMed ID: 21670176)
1. LEADER Program results for 2009: an activity and spectrum analysis of linezolid using 6,414 clinical isolates from 56 medical centers in the United States.
Farrell DJ; Mendes RE; Ross JE; Sader HS; Jones RN
Antimicrob Agents Chemother; 2011 Aug; 55(8):3684-90. PubMed ID: 21670176
[TBL] [Abstract][Full Text] [Related]
2. An international activity and spectrum analysis of linezolid: ZAAPS Program results for 2011.
Flamm RK; Mendes RE; Ross JE; Sader HS; Jones RN
Diagn Microbiol Infect Dis; 2013 Jun; 76(2):206-13. PubMed ID: 23478031
[TBL] [Abstract][Full Text] [Related]
3. LEADER surveillance program results for 2010: an activity and spectrum analysis of linezolid using 6801 clinical isolates from the United States (61 medical centers).
Flamm RK; Farrell DJ; Mendes RE; Ross JE; Sader HS; Jones RN
Diagn Microbiol Infect Dis; 2012 Sep; 74(1):54-61. PubMed ID: 22704791
[TBL] [Abstract][Full Text] [Related]
4. Linezolid Surveillance Results for the United States (LEADER Surveillance Program 2014).
Flamm RK; Mendes RE; Hogan PA; Streit JM; Ross JE; Jones RN
Antimicrob Agents Chemother; 2016 Apr; 60(4):2273-80. PubMed ID: 26833165
[TBL] [Abstract][Full Text] [Related]
5. Linezolid surveillance program results for 2008 (LEADER Program for 2008).
Farrell DJ; Mendes RE; Ross JE; Jones RN
Diagn Microbiol Infect Dis; 2009 Dec; 65(4):392-403. PubMed ID: 19913682
[TBL] [Abstract][Full Text] [Related]
6. LEADER surveillance program results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from the United States (50 medical centers).
Jones RN; Fritsche TR; Sader HS; Ross JE
Diagn Microbiol Infect Dis; 2007 Nov; 59(3):309-17. PubMed ID: 17720350
[TBL] [Abstract][Full Text] [Related]
7. Zyvox Annual Appraisal of Potency and Spectrum program: linezolid surveillance program results for 2008.
Jones RN; Ross JE; Bell JM; Utsuki U; Fumiaki I; Kobayashi I; Turnidge JD
Diagn Microbiol Infect Dis; 2009 Dec; 65(4):404-13. PubMed ID: 19913683
[TBL] [Abstract][Full Text] [Related]
8. United States resistance surveillance results for linezolid (LEADER Program for 2007).
Jones RN; Ross JE; Castanheira M; Mendes RE
Diagn Microbiol Infect Dis; 2008 Dec; 62(4):416-26. PubMed ID: 19022153
[TBL] [Abstract][Full Text] [Related]
9. TR-700 in vitro activity against and resistance mutation frequencies among Gram-positive pathogens.
Jones RN; Moet GJ; Sader HS; Mendes RE; Castanheira M
J Antimicrob Chemother; 2009 Apr; 63(4):716-20. PubMed ID: 19218276
[TBL] [Abstract][Full Text] [Related]
10. ZAAPS Program results for 2010: an activity and spectrum analysis of linezolid using clinical isolates from 75 medical centres in 24 countries.
Flamm RK; Farrell DJ; Mendes RE; Ross JE; Sader HS; Jones RN
J Chemother; 2012 Dec; 24(6):328-37. PubMed ID: 23174097
[TBL] [Abstract][Full Text] [Related]
11. In vitro activity of linezolid as assessed through the 2013 LEADER surveillance program.
Flamm RK; Mendes RE; Hogan PA; Ross JE; Farrell DJ; Jones RN
Diagn Microbiol Infect Dis; 2015 Apr; 81(4):283-9. PubMed ID: 25633420
[TBL] [Abstract][Full Text] [Related]
12. Molecular characterization of linezolid-resistant CoNS isolates in Japan.
Takaya A; Kimura A; Sato Y; Ishiwada N; Watanabe M; Matsui M; Shibayama K; Yamamoto T
J Antimicrob Chemother; 2015 Mar; 70(3):658-63. PubMed ID: 25381168
[TBL] [Abstract][Full Text] [Related]
13. Linezolid surveillance results for the United States: LEADER surveillance program 2011.
Flamm RK; Mendes RE; Ross JE; Sader HS; Jones RN
Antimicrob Agents Chemother; 2013 Feb; 57(2):1077-81. PubMed ID: 23254424
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of linezolid resistance in staphylococci and enterococci isolated from two teaching hospitals in Shanghai, China.
Tian Y; Li T; Zhu Y; Wang B; Zou X; Li M
BMC Microbiol; 2014 Nov; 14():292. PubMed ID: 25420718
[TBL] [Abstract][Full Text] [Related]
15. Summary of linezolid activity and resistance mechanisms detected during the 2012 LEADER surveillance program for the United States.
Mendes RE; Flamm RK; Hogan PA; Ross JE; Jones RN
Antimicrob Agents Chemother; 2014; 58(2):1243-7. PubMed ID: 24323470
[TBL] [Abstract][Full Text] [Related]
16. Linezolid-resistant clinical isolates of enterococci and Staphylococcus cohnii from a multicentre study in China: molecular epidemiology and resistance mechanisms.
Chen H; Wu W; Ni M; Liu Y; Zhang J; Xia F; He W; Wang Q; Wang Z; Cao B; Wang H
Int J Antimicrob Agents; 2013 Oct; 42(4):317-21. PubMed ID: 23880167
[TBL] [Abstract][Full Text] [Related]
17. Daptomycin activity tested against linezolid-nonsusceptible gram-positive clinical isolates.
Mendes RE; Jones RN; Deshpande LM; Ross JE; Sader HS
Microb Drug Resist; 2009 Dec; 15(4):245-9. PubMed ID: 19857129
[TBL] [Abstract][Full Text] [Related]
18. Stability of linezolid activity in an era of mobile oxazolidinone resistance determinants: results from the 2009 Zyvox® Annual Appraisal of Potency and Spectrum program.
Biedenbach DJ; Farrell DJ; Mendes RE; Ross JE; Jones RN
Diagn Microbiol Infect Dis; 2010 Dec; 68(4):459-67. PubMed ID: 21094428
[TBL] [Abstract][Full Text] [Related]
19. Results of the surveillance of Tedizolid activity and resistance program: in vitro susceptibility of gram-positive pathogens collected in 2011 and 2012 from the United States and Europe.
Sahm DF; Deane J; Bien PA; Locke JB; Zuill DE; Shaw KJ; Bartizal KF
Diagn Microbiol Infect Dis; 2015 Feb; 81(2):112-8. PubMed ID: 25488274
[TBL] [Abstract][Full Text] [Related]
20. ZAAPS Program results for 2015: an activity and spectrum analysis of linezolid using clinical isolates from medical centres in 32 countries.
Pfaller MA; Mendes RE; Streit JM; Hogan PA; Flamm RK
J Antimicrob Chemother; 2017 Nov; 72(11):3093-3099. PubMed ID: 28961701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
